New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - vinblastine sulfate 10mg - powder for injection - 10 mg - active: vinblastine sulfate 10mg excipient: benzyl alcohol sodium chloride water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - pentamidine isetionate -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - ketamine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - amikacin -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - atracurium besilate, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - atracurium besilate injection is indicated as an adjunct to general anaesthesia during surgery to relax skeletal muscles, and to facilitate endotracheal intubation and mechanical ventilation. it is also indicated to facilitate mechanical ventilation in intensive care unit (icu) patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - methotrexate, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - united kingdom: methotrexate injection is an anti-metabolite medicine and immunosuppressant. it is used in large doses to treat certain types of cancer such as breast cancer. in smaller doses it can be used to treat severe psoriasis, when it has not responded to other treatments. ireland: methotrexate is used to treat cancer, such as: lymphatic leukemia (disease of the blood or bone marrow), breast cancer, bone cancer, head and neck cancer, gynaecologic cancer (choriocarcinoma, trophoblastic disease ? tumor development directly associated with pregnancy), and non-hodgkin?s lymphoma. methotrexate can also be used to treat severe psoriasis, when it has not responded to other treatments.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - docetaxel - solution for infusion - docetaxel 10 mg / 1 ml - docetaxel - docetaxel - breast cancer: docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer. docetaxel in combination with trastuzumab, and carboplatin (tch) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer. non-small cell lung cancer: docetaxel is indicated for the treatment of patients with advanced non-small cell lung carcinoma. ovarian cancer: docetaxel is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy. prostate cancer: docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.esophageal cancer: docetaxel for the treatment of esophageal cancer. gastric cancer: docetaxel for the treatment of advanced gastric cancer. head and neck (scchn): docetaxel as monotherapy in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen. docetaxel in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - glycopyrronium bromide (glycopyrrolate) -

New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - furosemide 10 mg/ml; furosemide 10 mg/ml - solution for injection - 20 mg/2ml - active: furosemide 10 mg/ml excipient: sodium chloride sodium hydroxide water for injection active: furosemide 10 mg/ml excipient: sodium chloride sodium hydroxide water for injection - dbl™ frusemide injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. dbl™ frusemide injection is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.

New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - flucloxacillin sodium monohydrate 262.1mg equivalent to 250 mg flucloxicillin;   - powder for injection - 250 mg - active: flucloxacillin sodium monohydrate 262.1mg equivalent to 250 mg flucloxicillin